Influence of calcium and / or vitamin D supplementation in patients with Polycystic Ovarian Syndrome.
Not Applicable
Recruiting
- Conditions
- M01.774.500Polycystic Ovarian Syndrome and Health VolunteersC04.182.612.765
- Registration Number
- RBR-986tpd
- Lead Sponsor
- niversidade Federal de Minas Gerais - UFMG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- Not specified
Inclusion Criteria
Clinical trial: women with medical diagnosis of Polycystic Ovarian Syndrome; age between 18 and 40 years.
Exclusion Criteria
Type II diabetes; autoimmune disease; adrenal, renal and hepatic diseases; thyroid disorders; cancer or tumors; acute inflammatory disease; hyperprolactinemia; hypogonadism and pregnancy. Volunteers treated with the following medications will also be excluded: steroid and non-steroidal anti-inflammatories; isotretinoin; cyclosporin; antiretrovirals; insulin; metformin and oral contraceptives.
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method - Mean difference of at least 5 in the HOMA-B index between supplemented patients and placebo group.<br> - Mean difference of at least 100 ng / ml in CRP dosages between supplemented patients and placebo group.<br> - Mean difference of at least 2.5 mmol / l in nitric oxide dosages between supplemented patients and placebo group.
- Secondary Outcome Measures
Name Time Method Secondary outcomes are not expected